The stock of Kymera Therapeutics Inc (NASDAQ: KYMR) has increased by 7.79 when compared to last closing price of 37.22.Despite this, the company has seen a gain of 0.55% in its stock price over the last five trading days. globenewswire.com reported 2025-01-14 that KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and plans to initiate parallel Phase 2b trials in AD and asthma in late 2025 and early 2026, respectively KT-295 (TYK2) to advance into Phase 1 testing in 2Q25 with data expected in late 2025 KT-474/SAR444656 (IRAK4) Phase 2b dose-ranging studies in hidradenitis suppurativa (HS) and AD ongoing, with completion expected in 1H26 and mid-2026, respectively Novel oral immunology program with a first-in-class development candidate to be disclosed in 1H25 Well-capitalized with $850 1 million in cash and runway into mid-2027 Kymera to present its 2025 outlook at J.P. Morgan Annual Healthcare Conference on Tuesday, January 14, 2025, at 9:00 a.m.
Is It Worth Investing in Kymera Therapeutics Inc (NASDAQ: KYMR) Right Now?
The 36-month beta value for KYMR is also noteworthy at 2.21. There are mixed opinions on the stock, with 13 analysts rating it as a “buy,” 3 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for KYMR is 55.01M, and at present, short sellers hold a 15.95% of that float. The average trading volume of KYMR on January 15, 2025 was 441.65K shares.
KYMR’s Market Performance
KYMR’s stock has seen a 0.55% increase for the week, with a -10.87% drop in the past month and a -10.88% fall in the past quarter. The volatility ratio for the week is 7.31%, and the volatility levels for the past 30 days are at 6.41% for Kymera Therapeutics Inc The simple moving average for the past 20 days is -0.81% for KYMR’s stock, with a -2.83% simple moving average for the past 200 days.
Analysts’ Opinion of KYMR
Many brokerage firms have already submitted their reports for KYMR stocks, with BTIG Research repeating the rating for KYMR by listing it as a “Buy.” The predicted price for KYMR in the upcoming period, according to BTIG Research is $60 based on the research report published on December 10, 2024 of the previous year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see KYMR reach a price target of $55. The rating they have provided for KYMR stocks is “Market Perform” according to the report published on December 06th, 2024.
Wells Fargo gave a rating of “Overweight” to KYMR, setting the target price at $57 in the report published on December 02nd of the previous year.
KYMR Trading at -8.69% from the 50-Day Moving Average
After a stumble in the market that brought KYMR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.69% of loss for the given period.
Volatility was left at 6.41%, however, over the last 30 days, the volatility rate increased by 7.31%, as shares sank -4.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.84% lower at present.
During the last 5 trading sessions, KYMR rose by +0.55%, which changed the moving average for the period of 200-days by -0.12% in comparison to the 20-day moving average, which settled at $40.45. In addition, Kymera Therapeutics Inc saw -0.27% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KYMR starting from Chiniara Ellen, who sale 3,129 shares at the price of $41.75 back on Jan 06 ’25. After this action, Chiniara Ellen now owns 54,826 shares of Kymera Therapeutics Inc, valued at $130,645 using the latest closing price.
Chiniara Ellen, the Officer of Kymera Therapeutics Inc, proposed sale 3,129 shares at $41.59 during a trade that took place back on Jan 06 ’25, which means that Chiniara Ellen is holding shares at $130,135 based on the most recent closing price.
Stock Fundamentals for KYMR
Current profitability levels for the company are sitting at:
- -2.23 for the present operating margin
- 0.93 for the gross margin
The net margin for Kymera Therapeutics Inc stands at -1.91. The total capital return value is set at -0.2. Equity return is now at value -26.00, with -21.10 for asset returns.
Based on Kymera Therapeutics Inc (KYMR), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -1.41. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -806.89.
Currently, EBITDA for the company is -143.2 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 29.42. The receivables turnover for the company is 66.49for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.55.
Conclusion
In summary, Kymera Therapeutics Inc (KYMR) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
